Efficacy and Predictability of Cyclin-Dependent Kinase 4/6 Inhibitors in HER2-Positive Breast Cancer.

Muhammad Shahmir Abbasi, Muhammad Zubair Afzal, Tayyaba Sarwar, Holly A Gamlen-Steves

Abstract readReview

In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Machine learning and cox model-based prediction of CDK4/6 inhibitor outcomes in HR+/HER2 - metastatic breast cancer: a multicenter real-world study.Breast cancer research and treatment · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Muhammad Shahmir AbbasiDepartment of Geriatric Medicine, Rush University Medical Center, Chicago, IL 60612, USA.ORCID 0000-0002-7060-7436

Muhammad Zubair AfzalComprehensive Breast Program, Department of Medical Oncology, Dartmouth Cancer Center, Lebanon, NH 03755, USA.

Tayyaba SarwarDepartment of Internal Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH 03755, USA.

Holly A Gamlen-StevesDepartment of Internal Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH 03755, USA.ORCID 0000-0002-3746-2909

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HER2-positive breast cancer represents a biologically aggressive subtype associate with poor prognosis, despite advances in targeted therapies. Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), initially approved for hormone-receptor-positive, HER2-negative disease, are now being explored in HER2-positive settings due to their mechanistic synergy with the HER2 signaling pathway. This review synthesizes evolving clinical evidence from trials and highlights further research into biomarker discovery. CDK4/6i may redefine treatment paradigms in HER2-positive breast cancer, offering a potential, non-chemotherapy option with durable benefit in select patient populations.

Indexed as

breast cancercyclin-dependent kinase 4/6 inhibitorHER2 positivetargeted therapy

Identifiers

PMID40940886

DOI10.3390/cancers17172788

PMCPMC12427547

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.